Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19.

COVID-19 is a new disease caused by coronavirus SARS-CoV-2. It was first described in 2019, developed into an epidemic in January 2020 and has spread the global to the present COVID-19 pandemic. Specialized pro­resolving mediators (SPMs) may play a new role in the management of this lung disease because SPM actively stimulate the resolution of infectious inflammation and are organ protective in animal disease models. Many tissues have been suitable targets for treating inflammation with SPMs or their active precursors 18-HEPE, 17-HDHA and the 14-HDHA, in order to elicit dynamic resolution of inflammation. Here we discuss the possible mode of action of these substances in the management of SARS Covid 19.

Chronic Inflammation in PCOS: The Potential Benefits of Specialized Pro-Resolving Lipid Mediators (SPMs) in the Improvement of the Resolutive Response.

PCOS as the most common endocrine disorder of women in their reproductive age affects between 5-15 % of the female population. Apart from its cardinal symptoms, like irregular and anovulatory cycles, hyperandrogenemia and a typical ultrasound feature of the ovary, obesity, and insulin resistance are often associated with the disease. Furthermore, PCOS represents a status of chronic inflammation with permanently elevated levels of inflammatory markers including IL-6 and IL-18, TNF-α, and CRP. Inflammation, as discovered only recently, consists of two processes occurring concomitantly: active initiation, involving "classical" mediators including prostaglandins and leukotrienes, and active resolution processes based on the action of so-called specialized pro-resolving mediators (SPMs). These novel lipid mediator molecules derive from the essential ω3-poly-unsaturated fatty acids (PUFAs) DHA and EPA and are synthesized via specific intermediates. The role and benefits of SPMs in chronic inflammatory diseases like obesity, atherosclerosis, and Diabetes mellitus has become a subject of intense research during the last years and since PCOS features several of these pathologies, this review aims at summarizing potential roles of SPMs in this disease and their putative use as novel therapeutics.

Accumulation and Depuration of Pathogenic and Indicator Microorganisms by the bivalve mollusc, Chamelea gallina L, Under Controlled Laboratory Conditions.

The comparative accumulation and depuration processes for several microorganisms ( Escherichia coli , Salmonella typhimurium , Vibrio parahaemolyticus , Aeromonas hydrophila , Streptococcus faecalis , Staphylococcus aureus , and MS-2 coliphage) by the striped venus, Chamelea gallina , under controlled laboratory conditions were studied. Microorganisms accumulated rapidly in bivalves during the first 6 h, with accumulation rates between 3.2 to 360.5 organisms/h depending on the type of microorganism. The relative patterns and rates of elimination of the microorganisms suggest that they are eliminated from shellfish in two different ways. One is of a mechanical nature that results in microbial elimination during the first 12 h. The other elimination mechanism depends upon the microbial species and their accumulated number. All microorganisms tested were eliminated completely by the molluscs after 3 d of depuration, except MS-2 bacteriophages. Results indicate that MS-2 coliphages may be a more reliable indicator of the microbial depuration efficiency by the shellfish under laboratory conditions than E. coli .